FTO and acute myeloid leukemia: Additionally, inhibitors like FB23-2, FG-2216/IOX3, Rhein, Entacapone, and meclofenamic acid inhibit FTO activity, preventing the self-renewal and tumorigenic properties of AML and GBM [132–134].